Success Metrics

Clinical Success Rate
92.6%

Based on 25 completed trials

Completion Rate
93%(25/27)
Active Trials
4(11%)
Results Posted
44%(11 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_1
10
28%
Ph phase_4
5
14%
Ph phase_2
8
22%
Ph phase_3
12
33%
Ph not_applicable
1
3%

Phase Distribution

10

Early Stage

8

Mid Stage

17

Late Stage

Phase Distribution36 total trials
Phase 1Safety & dosage
10(27.8%)
Phase 2Efficacy & side effects
8(22.2%)
Phase 3Large-scale testing
12(33.3%)
Phase 4Post-market surveillance
5(13.9%)
N/ANon-phased studies
1(2.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.2%

25 of 29 finished

Non-Completion Rate

13.8%

4 ended early

Currently Active

4

trials recruiting

Total Trials

36

all time

Status Distribution
Active(5)
Completed(25)
Terminated(4)
Other(2)

Detailed Status

Completed25
Recruiting4
unknown2
Withdrawn2
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
36
Active
4
Success Rate
92.6%
Most Advanced
Phase 4

Trials by Phase

Phase 110 (27.8%)
Phase 28 (22.2%)
Phase 312 (33.3%)
Phase 45 (13.9%)
N/A1 (2.8%)

Trials by Status

completed2569%
not_yet_recruiting13%
recruiting411%
unknown26%
withdrawn26%
terminated26%

Recent Activity

Clinical Trials (36)

Showing 20 of 36 trialsScroll for more
NCT04368559Phase 3

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Completed
NCT07053774Phase 2

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Recruiting
NCT07409753Phase 2

Effects Of Intravenous Oxytocin On Peripheral Sensory Afferents Using Microneurography

Recruiting
NCT07389460Phase 3

Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)

Not Yet Recruiting
NCT06987305Phase 3

Intravenous rhTNK-tPA Before Stroke Thrombectomy in the Extended Time Window

Recruiting
NCT06192615Phase 3

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)

Recruiting
NCT06863467Phase 1

Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Completed
NCT04643457Phase 1

A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic Dermatitis

Completed
NCT02682225Phase 1

Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

Completed
NCT05070260Phase 2

ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo

Completed
NCT05496738Phase 1

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Completed
NCT03326245Phase 1

Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI

Completed
NCT04574947Phase 4

Lidocaine And Neuromonitoring in Thyroid Surgery

Completed
NCT02720692Phase 3

Evaluation of N1539 Following Major Surgery

Completed
NCT03667690Phase 3

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

Completed
NCT05018403Phase 1

First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects

Completed
NCT03579914Not Applicable

Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients

Completed
NCT03803007Phase 1

Acute Ischemic Stroke Interventional Study

Completed
NCT03825939Phase 4

Evaluating the Use of Tranexamic Acid (TXA) in Total Joint Arthroplasty

Terminated
NCT02734862Phase 2

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Completed

Drug Details

Intervention Type
DRUG
Total Trials
36